Krystal BiotechFRA:4KB +3.23%58 Days Payable is 52.56 as of Mar. 2026, which is 37% below its 10-year median of 82.94. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €262.63 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 707 Biotechnology companies, Krystal Biotech ranks worse than 64.64% on this metric.
The historical rank and industry rank for Krystal Biotech's Days Payable or its related term are showing as below:
FRA:4KB'
s Days Payable Range Over the Past 10 Years
Min: 57.64 Med: 82.94 Max: 478.55
Current: 57.64
During the past 10 years, Krystal Biotech's highest Days Payable was 478.55. The lowest was 57.64. And the median was 82.94.
FRA:4KB's Days Payable is ranked worse than 64.64% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs FRA:4KB: 57.64
Krystal Biotech's Days Payable
declined
from Mar. 2025 (70.95) to Mar. 2026 (52.56).
It may suggest that Krystal Biotechaccelerated paying its suppliers.
Krystal Biotech Days Payable Related Terms
Krystal Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Days Payable Comparison
For the Biotechnology subindustry, Krystal Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Krystal Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Days Payable of 52.56 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Krystal Biotech and its competitors. This is 37% below median its historical median of 82.94. Over the past decade, Krystal Biotech's Days Payable has ranged from 57.64 to 478.55. According to the industry distribution chart, Krystal Biotech ranks #457 out of 707 companies in the Biotechnology industry, placing it in the top 64.6%.
Is Krystal Biotech's Days Payable too high?
Krystal Biotech's current Days Payable of 52.56 is 37% below median its 10-year median of 82.94. Over the past 10 years, this metric has ranged from a low of 57.64 to a high of 478.55. The Biotechnology industry median Days Payable is 113.76. Krystal Biotech's value of 52.56 is 53.8% below this industry median. Based on the distribution chart, Krystal Biotech ranks #457 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Days Payable compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #457 out of 707 companies for Days Payable. This places Krystal Biotech in the lower half of its industry. The industry median Days Payable is 113.76. Krystal Biotech's value of 52.56 is 53.8% below this benchmark. Historically, Krystal Biotech's own Days Payable has ranged from 57.64 to 478.55 over the past decade. While the company's 10-year median is 82.94 vs. the industry median of 113.76, Krystal Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Days Payable of 52.56 is 53.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Days Payable is 52.56, which is 37% below median its own 10-year median of 82.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €262.63, compared to a current price of €313.40 — trading 19.3% above its estimated fair value. The current Days Payable is 52.56, which is 37% below median its 10-year median of 82.94 and 53.8% below the Biotechnology industry median of 113.76. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Days Payable is 52.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €313.40 is trading 19.3% above its estimated GF Value™ of €262.63.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Days Payable: 52.56 (37% below median its 10-year median of 82.94)
GF Value™: €262.63 vs. price of €313.40 (19.3% above fair value)
Industry Position: 53.8% below the Biotechnology median (#457 of 707)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
